The Pharmacy Times® Mental Health Resource Center is a comprehensive resource for clinical news and expert insights on conditions that affect mood, thinking, and behavior, including clinical depression, bipolar disorder, schizophrenia, anxiety, and post-traumatic stress disorder.
June 11th 2025
The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements
2.0 Credits / Psychiatry
View More
Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
3.0 Credits / Psychiatry
View More
Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies
1.0 Credit / Psychiatry
View More
Bipolar Patients at High Risk for Self-Harm Recurrence
December 5th 2014Up to 60% of patients diagnosed with bipolar disorder cause harm to themselves at least once throughout their lifetimes, and at least 5% of them commit suicide. Nevertheless, few prospective studies have examined self-harm in BPD patients specifically.
Read More
Ethnic Minorities Still Receiving Inferior Mental Health Treatment, Says APA Journal
December 5th 2014Primary care that includes mental health screenings and treatments that take into account a patient's language and cultural background can help address mental health care disparities among ethnic minorities.
Read More
FDA Grants Priority Review to Bipolar Indication for Schizophrenia Drug
November 14th 2014Actavis's supplemental New Drug Application for asenapine to treat manic or mixed episodes related to bipolar disorder in pediatric patients has been accepted by the FDA and given priority review status.
Read More